Disparities in Achieving LDL-C Goals After Revascularization in a Diverse Real-World Cohort
Abstract Body (Do not enter title and authors here): Background Guidelines and large clinical trials support the cardiovascular benefits of low-density lipoprotein cholesterol (LDL-C) testing and treatment with lipid-lowering therapies (LLT). Research Questions What characteristics influence attainment of guideline recommended LDL-C goals in patients undergoing coronary (CAD) or peripheral arterial (PAD) revascularization? Goals We analyzed the rates of LDL-C testing within 6 months and LDL-C goal attainment (<70 mg/dL) in a cohort of patients undergoing CAD or PAD revascularization. Methods We retrospectively analyzed 8,172 patients from a large health network who underwent percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or peripheral artery revascularization from 2018-2023. Patients without follow-up LDL-C testing >30 days after revascularization were excluded. The associations between clinical variables and LDL-C goal attainment were assessed with logistic regression analysis. Results Only about half of the patients (4,319) had LDL-C tests >30 days after their revascularization and were included in the analysis. The median age was 68 years, 2,729 (63%) were male, 1,848 (43%) were Hispanic, 928 (21%) were non-Hispanic Black and 663 (15%) were non-Hispanic White. Overall, 3,373 (78%) patients underwent PCI, 857 (20%) CABG, and 89 (2%) PAD revascularization. Median time to follow-up testing was 11 months (Panel A). Those with earlier follow-up testing, <6 months (35%), had higher utilization of high-intensity statins, ezetimibe, and PCSK9 inhibitors. A follow-up LDL-C <70 mg/dL was achieved in 2,259 (52%) patients with 1,294 (30%) having LDL-C <55 mg/dL (Panel B). Female sex, non-Hispanic Black race/ethnicity, presence of obesity and longer time to LDL-C testing were independently associated with a lower likelihood of achieving LDL-C <70 mg/dL after multivariable adjustment (Panel C). Conclusions LDL-C testing and guideline recommended goal attainment were low and female, non-Hispanic Black patients and those with obesity were less likely to reach optimal LDL-C values. Future preventive efforts must focus on efficiently standardizing and implementing an approach to LDL-C testing and lowering after revascularization.
Greenberg, Garred
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Lipsitz, Evan
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Forest, Stephen
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Scotti, Andrea
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Latib, Azeem
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Garcia, Mario
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Rodriguez, Carlos
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Gulati, Martha
( Cedars-Sinai Medical Center
, Los Angeles
, California
, United States
)
Slipczuk, Leandro
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Lorenzatti, Daniel
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Filtz, Annalisa
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Jaspan, Vita
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Park, Christine
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Kalich, Bethany
( Amgen Inc
, Thousand Oaks
, California
, United States
)
Kathe, Niranjan
( Amgen Inc
, Thousand Oaks
, California
, United States
)
Dipalo, Katherine
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Browne, Constance
( Montefiore Medical Center/Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Author Disclosures:
Garred Greenberg:DO NOT have relevant financial relationships
| Evan Lipsitz:No Answer
| Stephen Forest:DO NOT have relevant financial relationships
| Andrea Scotti:No Answer
| Azeem Latib:DO have relevant financial relationships
;
Consultant:Edwards Lifesciences:Active (exists now)
; Advisor:Supira:Active (exists now)
; Advisor:Shifamed:Active (exists now)
; Advisor:Boston Scientific:Active (exists now)
; Advisor:Medtronic:Active (exists now)
; Advisor:Abbott Vascular:Active (exists now)
| Mario Garcia:DO have relevant financial relationships
;
Royalties/Patent Beneficiary:Elsevier:Active (exists now)
; Individual Stocks/Stock Options:Pfizer:Active (exists now)
; Royalties/Patent Beneficiary:Wolters-Kluwer:Active (exists now)
| Carlos Rodriguez:DO NOT have relevant financial relationships
| Martha Gulati:DO NOT have relevant financial relationships
| Leandro Slipczuk:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Philips:Active (exists now)
; Research Funding (PI or named investigator):Amgen:Active (exists now)
| Daniel Lorenzatti:DO NOT have relevant financial relationships
| Annalisa Filtz:DO NOT have relevant financial relationships
| Vita Jaspan:DO NOT have relevant financial relationships
| Christine Park:DO NOT have relevant financial relationships
| Bethany Kalich:No Answer
| Niranjan Kathe:DO have relevant financial relationships
;
Employee:Amgen Inc:Active (exists now)
; Individual Stocks/Stock Options:Amgen Inc:Active (exists now)
| Katherine DiPalo:DO NOT have relevant financial relationships
| Constance Browne:No Answer